Clinical Trial Update: Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (GLORA-4) is evaluating lisaftoclax (APG-2575) in combination with azacitidine for higher-risk myelodysplastic syndromes and is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Lisaftoclax (APG-2575)

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Higher-risk Myelodysplastic Syndrome | Phase 3 | Status: RECRUITING